Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA

NCT07242014 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.

NCT NCT07242014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07242014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA
Lead sponsor
The First Affiliated Hospital of Xiamen University
Phase
Not applicable
Overall status
Recruiting
Start date
September 1, 2025
Completion date
October 1, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acp3, pet/ct, prostate cancer